10q10k10q10k.net
HUTCHMED (China) Ltd

HUTCHMED (China) LtdHCMEarnings & Financial Report

Nasdaq

HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.

Q4 2025Q2 2025Q4 2024Q2 2024Q2 2023Q2 2022

Revenue

$202.0M

Gross Profit

$165.2K

Operating Profit

$-196.8M

Net Profit

$-162.9M

Gross Margin

0.1%

Operating Margin

-97.4%

Net Margin

-80.6%

YoY Growth

28.4%

EPS

$-0.19

Financial Flow

HUTCHMED (China) Ltd Q2 2022 Financial Summary

HUTCHMED (China) Ltd reported revenue of $202.0M (up 28.4% YoY) for Q2 2022, with a net profit of $-162.9M (down 59.0% YoY) (-80.6% margin). Cost of goods sold was $201.9M, operating expenses totaled $196.9M.

Key Financial Metrics

Total Revenue$202.0M
Net Profit$-162.9M
Gross Margin0.1%
Operating Margin-97.4%
Report PeriodQ2 2022

HUTCHMED (China) Ltd Quarterly Revenue & Net Profit History

HUTCHMED (China) Ltd results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 2025$270.8M-16.5%$2.0M0.7%
Q2 2025$277.7M-9.2%$455.0M163.8%
Q4 2024$324.5M—$11.9M3.7%
Q2 2024$305.7M-42.6%$25.8M8.4%
Q2 2023$532.9M+163.7%$168.6M31.6%
Q2 2022$202.0M+28.4%$-162.9M-80.6%

Income Statement

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Revenue$202.0M$532.9M$305.7M$324.5M$277.7M$270.8M
YoY Growth28.4%163.7%-42.6%N/A-9.2%-16.5%

Balance Sheet

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Assets$1.19B$1.30B$1.26B$1.27B$1.78B$1.75B
Liabilities$342.5M$497.5M$508.9M$502.3M$534.0M$501.8M
Equity$799.7M$782.0M$740.1M$759.9M$1.23B$1.24B

Cash Flow

Q2 2022Q2 2023Q2 2024Q4 2024Q2 2025Q4 2025
Operating CF$-89.9M$226.4M$-39.8M$40.3M$-72.9M$8.2M